New panel date Guilford's Gliadel

The FDA's Oncologic Drugs Advisory Committee moved to Dec. 6 from Dec. 4 its review of GLFD's sNDA for Gliadel wafer carmustine implant as first-line therapy to treat malignant glioma. Gliadel is mark...